Gentamicin Inj Rx
Generic Name and Formulations:
Gentamicin sulfate 40mg/mL; IM, or IV inj after dilution; contains sulfites.
Various generic manufacturers
Indications for Gentamicin Inj:
Serious susceptible infections.
Obesity: Base dose on lean body mass. Usual duration 7–10 days. 1mg/kg IM or IV every 8 hours; max 5mg/kg/day. For alternative dosing regimens (eg, extended intervals) see literature.
Premature and infants <1 week: 2.5mg/kg every 12 hours. Neonates: 2.5mg/kg every 8 hours. Others: 2–2.5mg/kg every 8 hours.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >12micrograms/mL (when dosed at conventional intervals) and trough levels >2micrograms/mL. Renal impairment: reduce dose, see literature; maintain adequate hydration. Prolonged use or excessive doses. Asthma. Neuromuscular disorders. Elderly. Pregnancy (Cat.D): not recommended.
Avoid concomitant furosemide, ethacrynic acid, other nephro/neurotoxic drugs including cephalosporins. May potentiate neuromuscular blockade.
Nephro- or neurotoxicity, respiratory depression, lethargy, confusion, depression, visual disturbances, elevated liver enzymes, blood dyscrasias.
Formerly known under the brand names Garamycin, Gentafair.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Risk of Opioid-Benzodiazepine Overlap Up for Dual Prescribing
- Minority Residents Experience Burdens Linked to Race/Ethnicity
- Tips Provided for Budgeting in Medical Residency
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease